This morning ICER issued the Evidence Report assessing the comparative clinical effectiveness and value of inclisiran (Novartis), bempedoic acid (Nexletol®, Esperion Therapeutics), and bempedoic acid/ezetimibe (Nexlizet™, Esperion Therapeutics) for treating heterozygous familial hypercholesterolemia and for secondary prevention of atherosclerotic cardiovascular disease.
The evidence suggests that inclisiran can substantially lower LDL-C with limited safety concerns, and with a less frequent regimen that may enhance therapy adherence; ICER recommends an annual health-benefit price benchmark range of $3,600-$6,000. Also, bempedoic acid provides a new oral treatment option that may be helpful particularly for patients who are not able to take statins; however, a discount of at least 36% discount off its list price would be needed to reach the top end of our benchmark range of $1,600-$2,600 per year. ICER will be hosting a public meeting to discuss these findings on February 5. Read more here.
